Arterial myeloperoxidase in the detection and treatment of vulnerable atherosclerotic plaque: a new dawn for an old light
Cardiovascular Research · 17.03.2023 · 119 (1) · 112-120
DOI: 10.1093/cvr/cvac081 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Research, online erschienen am 19.05.2022. Verfasst von James Nadel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Heart Research Institute, The University of Sydney, 7 Eliza St, Newtown, 2042 Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Plaque, Atherosclerotic, Atherosclerosis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: National Health & Medical Research Council of Australia, National Heart Foundation, and the University of New South Wales, NSW Department of Health.
Abstract (Originalsprache)
Intracellular myeloperoxidase (MPO) plays a specific role in the innate immune response; however, upon release into the extracellular space in the setting of inflammation, drives oxidative tissue injury. Extracellular MPO has recently been shown to be abundant in unstable atheroma and causally linked to plaque destabilization, erosion, and rupture, identifying it as a potential target for the surveillance and treatment of vulnerable atherosclerosis. Through the compartmentalization of MPO’s protective and deleterious effects, extracellular MPO can be selectively detected using non-invasive molecular imaging and targeted by burgeoning pharmacotherapies. Given its causal relationship to plaque destabilization coupled with an ability to preserve its beneficial properties, MPO is potentially a superior translational inflammatory target compared with other immunomodulatory therapies and imaging biomarkers utilized to date. This review explores the role of MPO in plaque destabilization and provides insights into how it can be harnessed in the management of patients with vulnerable atherosclerotic plaque.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Heart Research Institute, The University of Sydney, 7 Eliza St, Newtown, 2042 Sydney, NSW, Australia.
- Cardiology Department, St Vincent's Hospital, Sydney, Australia.
- School of Medicine, University of New South Wales, Sydney, Australia.
- School of Life and Environmental Sciences, The University of Sydney, Sydney, Australia.
ORCID-Profile: Roland Stocker
Förderung
- National Health & Medical Research Council of Australia
- National Heart Foundation, and the University of New South Wales
- NSW Department of Health
- Senior Principal Research Fellowship
Zitieren
APA
Nadel, J., Jabbour, A., & Stocker, R. (2023). Arterial myeloperoxidase in the detection and treatment of vulnerable atherosclerotic plaque: a new dawn for an old light. Cardiovascular Research, 119(1), 112-120. https://doi.org/10.1093/cvr/cvac081
Vancouver
Nadel J, Jabbour A, Stocker R. Arterial myeloperoxidase in the detection and treatment of vulnerable atherosclerotic plaque: a new dawn for an old light. Cardiovascular Research. 2023;119(1):112-120. doi:10.1093/cvr/cvac081
BibTeX
@article{Nadel2023,
author = {Nadel, James and Jabbour, Andrew and Stocker, Roland},
title = {Arterial myeloperoxidase in the detection and treatment of vulnerable atherosclerotic plaque: a new dawn for an old light},
journal = {Cardiovascular Research},
year = {2023},
volume = {119},
number = {1},
pages = {112--120},
doi = {10.1093/cvr/cvac081}
}
EUVIMED